menu
    • menu
    [{"orgOrder":0,"company":"Versantis","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Genfit"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Lixudebart","moa":"CLDN1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alentis Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Therapeutics \/ Morningside Ventures"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

                            Details : ALE.F02 is a highly selective anti-CLDN1 mAb that recognizes pathological overexpressed and conformation-dependent CLDN1 epitopes on transformed epithelial cells and is being investigated for the treatment of fibrotic disease in the kidney, lung and live...

                            Product Name : ALE.F02

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study

                            Details : ALE.F02 is a mAb which works by targeting Claudin-1 (CLDN1), designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis.

                            Product Name : ALE.F02

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 26, 2023

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Jeito Capital

                            Deal Size : $105.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1

                            Details : The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.

                            Product Name : ALE.F02

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 13, 2023

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Jeito Capital

                            Deal Size : $105.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Genfit

                            Deal Size : $107.6 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, Expanding its Portfolio in Liver Disease...

                            Details : VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.

                            Product Name : VS-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 19, 2022

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Genfit

                            Deal Size : $107.6 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Versantis Presents New VS-01 Data at The International Liver Congress 2022

                            Details : Data showing both single and repeated intraperitoneal administrations of VS-01 reduced the concentration of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) related t...

                            Product Name : VS-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 24, 2022

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Alentis Therapeutics

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

                            Details : Alentis dosed first cohort of healthy participants in Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1 for treatment of liver and kidney fibrosis. ALE.F02 has demonstrated compelling safety and efficacy in preclinic...

                            Product Name : ALE.F02

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 01, 2022

                            Lead Product(s) : Lixudebart

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed

                            Versantis

                            Switzerland arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

                            Details : VS-01 is a potentially lifesaving, multi-organ support therapy that aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins following paracentesis.

                            Product Name : VS-01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : VS-01

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth